Innovative Nanobody Targeting CTLA4 and GPC3 for Advanced Liver Cancer Therapy
VHH-P787 is a humanized single-domain nanobody engineered to target cytotoxic T-lymphocyte associated protein 4 (CTLA4) and glypican 3 (GPC3). Currently under biological testing, this next-generation biologic is designed to address the pressing need for effective therapies in liver cancer. By simultaneously modulating immune checkpoints and recognizing tumor-specific antigens, VHH-P787 offers a promising therapeutic strategy for liver cancer. The dual-targeting approach leverages the role of CTLA4 in immune suppression and the tumor specificity of GPC3, positioning VHH-P787 as a unique molecule in the evolving landscape of liver cancer treatment.
| Candidate | VHH-P787 |
| Target | cytotoxic T-lymphocyte associated protein 4 (CTLA4) glypican 3 (GPC3) |
| Modality | humanized bispecific VHH |
| Indication | Liver Cancer |
Licensing Opportunity
VHH-P787 is available for out-licensing to strategic partners seeking first-in-class nanobody therapeutics for liver cancer. We welcome industry collaboration to accelerate its clinical and commercial development.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P787 |
Modality
VHH-P787 utilizes a single-domain antibody modality, classified as a nanobody. Distinct from conventional antibodies, nanobodies are characterized by a single variable domain, resulting in a small molecular size and remarkable structural stability. These features confer superior tissue penetration, enabling more effective localization within solid tumors such as those found in liver cancer. The inherent high stability and solubility of nanobodies enhance manufacturability and bio-distribution, potentially translating to improved therapeutic impact. VHH-P787’s uniquely engineered structure supports its dual specificity, optimizing immune modulation and tumor antigen recognition where conventional antibodies may be limited.
Target
CTLA4 is an immune checkpoint receptor predominantly expressed on T cells, known for downregulating immune responses to maintain self-tolerance. GPC3 is a membrane-bound heparan sulfate proteoglycan frequently overexpressed in hepatocellular carcinoma and largely absent from normal adult tissues. CTLA4 and GPC3 together represent highly actionable targets in liver cancer. CTLA4 allows for tumor-induced immune evasion, while GPC3 serves as a marker of malignant transformation in hepatic cells. VHH-P787 is designed to bind both CTLA4 and GPC3, providing dual therapeutic leverage: activating anti-tumor immunity via CTLA4 modulation and achieving selective tumor targeting by recognizing GPC3. Strategically, dual-targeting enhances the breadth of anti-cancer effects and provides a strong competitive differentiation in liver cancer therapy pipelines.
Mechanism of Action
VHH-P787 acts by binding to GPC3 expressed on the surface of liver cancer cells and engaging CTLA4-associated T cell receptor complexes. This dual mechanism enables VHH-P787 to block GPC3-mediated tumor cell signaling and simultaneously modulate T cell activation through CTLA4. By inhibiting immune checkpoint signaling and targeting a tumor-restricted antigen, VHH-P787 potentiates anti-tumor immune responses, potentially overcoming mechanisms of immune escape frequently observed in liver cancer. In addition, the nanobody platform supports further development as antibody-drug conjugates or multispecific antibody formats, expanding the therapeutic scope across oncological and immunological targets.
Liver Cancer
Liver cancer is a leading cause of cancer-related mortality worldwide, with hepatocellular carcinoma being the most prevalent histological subtype. This malignancy is often diagnosed at an advanced stage, contributing to poor prognoses. Major treatment modalities include surgical resection, liver transplantation, locoregional therapies, systemic chemotherapy, and targeted therapies, such as kinase inhibitors and immune checkpoint modulators. However, therapeutic outcomes remain suboptimal due to tumor heterogeneity, resistance mechanisms, and limited efficacy of available immunotherapies. There exists a significant unmet need for innovative treatments that combine targeted tumor recognition with effective immune activation. VHH-P787, through its dual-specific nanobody approach targeting CTLA4 and GPC3, addresses these challenges by potentially delivering selective cytotoxicity to tumor cells and restoring anti-tumor immunity. Its novel modality and molecular targets offer hope for enhanced clinical outcomes and expanded options in a field with limited therapeutic innovation.